Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 2
2017 2
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Outcomes of Intensity-modulated Carbon-ion Radiotherapy for Bone and Soft Tissue Tumors.
Takakusagi Y, Koge H, Kano K, Shima S, Tsuchida K, Mizoguchi N, Yoshida D, Kamada T, Katoh H. Takakusagi Y, et al. Anticancer Res. 2023 Jun;43(6):2777-2781. doi: 10.21873/anticanres.16446. Anticancer Res. 2023. PMID: 37247930
There was one death during the observation period, which occurred 7.0 months after the initiation of treatment. ...Acute toxicity of Grade 2 or higher was seen in 2 patients with Grade 2 pharyngeal mucositis. Late toxicities of Grade 2 or higher included 1 ca …
There was one death during the observation period, which occurred 7.0 months after the initiation of treatment. ...Acute toxicity of …
Cetuximab Plus Concurrent Radiotherapy in Patients With Nasopharyngeal Carcinoma.
Yamauchi M, Sato Y, Ishida T, Minesaki A, Shimazaki E, Kuratomi Y. Yamauchi M, et al. In Vivo. 2023 Sep-Oct;37(5):2224-2228. doi: 10.21873/invivo.13323. In Vivo. 2023. PMID: 37652522 Free PMC article.
The 1- and 3-year overall survival rates were 85.7% and 47.6%, respectively. The most common adverse events (AEs) were pharyngeal mucositis (100%), radiation dermatitis (100%), anorexia (28.6%), weight loss (28.6%), acneiform rash (28.6%), and dry mouth (28.6%). Gra …
The 1- and 3-year overall survival rates were 85.7% and 47.6%, respectively. The most common adverse events (AEs) were pharyngeal …
Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
Ota Y, Kodaira T, Fujii H, Shimokawa M, Yokota T, Nakashima T, Monden N, Homma A, Ueda S, Akimoto T. Ota Y, et al. Int J Clin Oncol. 2022 Nov;27(11):1675-1683. doi: 10.1007/s10147-022-02228-3. Epub 2022 Aug 24. Int J Clin Oncol. 2022. PMID: 36001247
N stage, T stage, and comorbidity were significantly associated with TCR. Major AEs of grade 3 or higher were pharyngeal mucositis (48.5%), radiation dermatitis (45.6%), and oral mucositis (40.4%). Pneumonitis was observed in 12 patients (7.0%); 6 cases (3.5% …
N stage, T stage, and comorbidity were significantly associated with TCR. Major AEs of grade 3 or higher were pharyngeal mucositis …
Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy.
Moroney LB, Helios J, Ward EC, Crombie J, Wockner LF, Burns CL, Spurgin AL, Blake C, Kenny L, Hughes BG. Moroney LB, et al. Oral Oncol. 2017 Jan;64:1-8. doi: 10.1016/j.oraloncology.2016.11.009. Epub 2016 Nov 25. Oral Oncol. 2017. PMID: 28024718
Dysphagia and associated acute toxicities were monitored weekly during treatment and at weeks 2, 4 and 12 post treatment using the CTCAE v4, Functional Oral Intake Score and National Dysphagia Diet Descriptors. RESULTS: 75% experienced Grade 2-3 dysphagia. Over 70% had gra …
Dysphagia and associated acute toxicities were monitored weekly during treatment and at weeks 2, 4 and 12 post treatment using the CTCAE v4, …
A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.
Wong KH, Kuciejewska A, Sharabiani MTA, Ng-Cheng-Hin B, Hoy S, Hurley T, Rydon J, Grove L, Santos A, Ryugenji M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL. Wong KH, et al. Radiother Oncol. 2017 Feb;122(2):207-211. doi: 10.1016/j.radonc.2016.06.015. Epub 2016 Jul 5. Radiother Oncol. 2017. PMID: 27393218 Free PMC article. Clinical Trial.
The primary endpoint was the incidence of severe OM (CTCAE grade 3) during and up to week 8 post-radiotherapy. Secondary endpoints include pharyngeal mucositis, dysphagia, pain and quality of life. RESULTS: The intervention (n=108) and control (n=107) arms were well …
The primary endpoint was the incidence of severe OM (CTCAE grade 3) during and up to week 8 post-radiotherapy. Secondary endpoints include …
Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu YP, Wen YH, Tang J, Wei Y, You R, Zhu XL, Li J, Chen L, Ling L, Zhang N, Zou X, Hua YJ, Chen YM, Chen L, Lu LX, Chen MY, Wen WP. Liu YP, et al. Lancet Oncol. 2021 Mar;22(3):381-390. doi: 10.1016/S1470-2045(20)30673-2. Epub 2021 Feb 15. Lancet Oncol. 2021. PMID: 33600761 Clinical Trial.
We included patients aged 18-70 years with a Karnofsky Performance Status score of at least 70 who were histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the po …
We included patients aged 18-70 years with a Karnofsky Performance Status score of at least 70 who were histopathologically diagnosed …
Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy.
Blake C, Lai R, Brown T, Pelecanos A, Moroney L, Helios J, Smith D, Hughes BGM, Kenny L, Chua B, Bauer J. Blake C, et al. J Hum Nutr Diet. 2024 Feb;37(1):182-192. doi: 10.1111/jhn.13243. Epub 2023 Sep 22. J Hum Nutr Diet. 2024. PMID: 37737485
The present study aimed to determine how treatment-related acute toxicities affect nutrition outcomes in patients with head and neck cancer. METHODS: A prospective observational study was conducted in 194 patients undergoing curative intent H-IMRT with or without other tre …
The present study aimed to determine how treatment-related acute toxicities affect nutrition outcomes in patients with head and neck cancer. …
Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
Boscolo-Rizzo P, Tirelli G, Mantovani M, Baggio V, Lupato V, Spinato G, Gava A, Da Mosto MC. Boscolo-Rizzo P, et al. Eur Arch Otorhinolaryngol. 2015 Nov;272(11):3491-8. doi: 10.1007/s00405-014-3369-8. Epub 2014 Nov 4. Eur Arch Otorhinolaryngol. 2015. PMID: 25367705
The complete response rate after CCRT was 90.7%. The main limiting toxicity was grade 3 and 4 pharyngeal mucositis (46.7%). Five-year cumulative rate of locoregional control (LRC), distant control (DC), overall survival (OS), and event-free survival (EFS) was 80.1, …
The complete response rate after CCRT was 90.7%. The main limiting toxicity was grade 3 and 4 pharyngeal mucositis (46.7%). Fi …
Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).
Tahara M, Kiyota N, Mizusawa J, Nakamura K, Hayashi R, Akimoto T, Hasegawa Y, Iwae S, Monden N, Matsuura K, Fujii H, Onozawa Y, Homma A, Kubota A, Fukuda H, Fujii M. Tahara M, et al. Cancer Sci. 2015 Jun;106(6):726-733. doi: 10.1111/cas.12657. Epub 2015 Apr 1. Cancer Sci. 2015. PMID: 25781202 Free PMC article. Clinical Trial.
After a median follow-up of 3.52 years, 3-year local progression-free survival was 62.2%, with 3-year progression-free survival of 60.0%, 3-year overall survival of 64.4%, and 3-year time to treatment failure of 48.9%. Grade 3 or 4 toxicity included pharyngeal mucositis …
After a median follow-up of 3.52 years, 3-year local progression-free survival was 62.2%, with 3-year progression-free survival of 60.0%, 3- …